|
|
|
|
|
|
|
|
March 9, 2010
HAMPTON, Va.--(BUSINESS WIRE)--HST Global, Inc. (OTCBB:HSTC)today announced that Dr. James Forsythe, MD, HMD, is experiencing continuous success with his Forsythe Immune Therapy (FIT) Protocol. Dr. James Forsythe, MD, HMD, is a board certified oncologist and a member of HST Global Inc.’s Board of Directors and Scientific Advisory Board.
Dr. Forsythe’s existing study is meeting with 70-80% efficacy in clinical treatment of Stage IV cancers in a test of 450 patients. The highlight of the study is in stage IV prostate cancer where they have met with 86% efficacy with prostate cancer patients over 55 months through the application of his "FIT" Protocol.
Ronald Howell President and CEO of HST Global, Inc. stated, "We are encouraged by the continued success Dr. Forsythe is experiencing with his FIT protocol. The updated study results demonstrate the efficacy of the FIT Protocol."
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.